These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 10099658)

  • 1. A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma.
    O'Reilly EM; Ilson DH; Saltz LB; Heelan R; Martin L; Kelsen DP
    Cancer Invest; 1999; 17(3):195-200. PubMed ID: 10099658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly systemic combination of cisplatin and interferon alpha 2a in diffuse malignant pleural mesothelioma.
    Purohit A; Moreau L; Dietemann A; Seibert R; Pauli G; Wihlm JM; Quoix E
    Lung Cancer; 1998 Nov; 22(2):119-25. PubMed ID: 10022219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP).
    Parra HS; Tixi L; Latteri F; Bretti S; Alloisio M; Gravina A; Lionetto R; Bruzzi P; Dani C; Rosso R; Cosso M; Balzarini L; Santoro A; Ardizzoni A
    Cancer; 2001 Aug; 92(3):650-6. PubMed ID: 11505411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.
    Metintas M; Ozdemir N; Uçgun I; Elbek O; Kolsuz M; Mutlu S; Metintas S
    Chest; 1999 Aug; 116(2):391-8. PubMed ID: 10453867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
    Soulié P; Ruffié P; Trandafir L; Monnet I; Tardivon A; Terrier P; Cvitkovic E; Le Chevalier T; Armand JP
    J Clin Oncol; 1996 Mar; 14(3):878-85. PubMed ID: 8622036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.
    Ron IG; Mordish Y; Eisenthal A; Skornick Y; Inbar MJ; Chaitchik S
    Cancer Immunol Immunother; 1994 Jun; 38(6):379-84. PubMed ID: 8205559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Ilson DH; Sirott M; Saltz L; Heelan R; Huang Y; Keresztes R; Kelsen DP
    Cancer; 1995 May; 75(9):2197-202. PubMed ID: 7712428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin (CBDCA) plus alpha interferon in metastatic non-small cell lung cancer. A Hoosier Oncology Group phase II trial.
    Mandanas R; Einhorn LH; Wheeler B; Ansari R; Lutz T; Miller ME
    Am J Clin Oncol; 1993 Dec; 16(6):519-21. PubMed ID: 8256769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
    Hughes A; Calvert P; Azzabi A; Plummer R; Johnson R; Rusthoven J; Griffin M; Fishwick K; Boddy AV; Verrill M; Calvert H
    J Clin Oncol; 2002 Aug; 20(16):3533-44. PubMed ID: 12177114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.
    Upham JW; Musk AW; van Hazel G; Byrne M; Robinson BW
    Aust N Z J Med; 1993 Dec; 23(6):683-7. PubMed ID: 8141698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II clinical trial of 13-cis-retinoic acid and interferon-alpha-2a in patients with advanced esophageal carcinoma.
    Enzinger PC; Ilson DH; Saltz LB; Martin LK; Kelsen DP
    Cancer; 1999 Mar; 85(6):1213-7. PubMed ID: 10189124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide, mesna, and interferon-alpha2A combination chemoimmunotherapy in malignant mesothelioma: results of a single center in central anatolia.
    Altinbas M; Er O; Ozkan M; Coskun HS; Gulmez I; Ekici E; Kaplan B; Eser B; Ozesmi M
    Med Oncol; 2004; 21(4):359-66. PubMed ID: 15579920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma.
    Shin DM; Fossella FV; Umsawasdi T; Murphy WK; Chasen MH; Walsh G; Komaki R; McMurtrey MJ; Hong WK
    Cancer; 1995 Dec; 76(11):2230-6. PubMed ID: 8635025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B.
    Vogelzang NJ; Goutsou M; Corson JM; Suzuki Y; Graziano S; Aisner J; Cooper MR; Coughlin KM; Green MR
    Cancer Chemother Pharmacol; 1990; 27(3):239-42. PubMed ID: 2265461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
    Katirtzoglou N; Gkiozos I; Makrilia N; Tsaroucha E; Rapti A; Stratakos G; Fountzilas G; Syrigos KN
    Clin Lung Cancer; 2010 Jan; 11(1):30-5. PubMed ID: 20085865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma.
    Ardizzoni A; Pennucci MC; Castagneto B; Mariani GL; Cinquegrana A; Magri D; Verna A; Salvati F; Rosso R
    Am J Clin Oncol; 1994 Feb; 17(1):80-2. PubMed ID: 8311014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study.
    Fizazi K; Doubre H; Le Chevalier T; Riviere A; Viala J; Daniel C; Robert L; Barthélemy P; Fandi A; Ruffié P
    J Clin Oncol; 2003 Jan; 21(2):349-54. PubMed ID: 12525529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.